MoneyWorks4Me

Neuland Laboratories reports 12% rise in Q2 net profit

11 Nov 2013 Evaluate

Neuland Laboratories has reported results for the second quarter ended September 30, 2013.

The company has reported 11.68% rise in its net profit at Rs 3.44 crore for the quarter as compared to Rs 3.08 crore for the same quarter in the previous year. However, total income from operation of the company has decreased by 10.97% at Rs 105.09 crore for quarter under review as compared to Rs  118.04 crore for the quarter ended September 30, 2012.

Neuland Laboratories is engaged in manufacturing of Salbutamol Sulphate. The company has has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions.

Neuland Laboratories Share Price

23380.00 157.85 (0.68%)
14-Aug-2026 15:32 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1924.90
Dr. Reddys Labs. 1202.00
Cipla 1450.00
Lupin 2235.00
Zydus Lifesciences 1140.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: